Eliot Charles, MiroBio executive chairman

Ox­ford spin­out nabs al­most $100M in new cash to test PD-1 in au­toim­mune dis­eases and hunt for a CEO

Af­ter about 15 years in an Ox­ford lab and three more years in the up­start world fol­low­ing a 2019 spin­out, Miro­Bio is ready to en­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.